XERIS BIOPHARMA HOLDINGS, INC. Operating Costs and Expenses
XERIS BIOPHARMA HOLDINGS, INC. (XERS) reported Operating Costs and Expenses of $86.93 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OperatingCostsAndExpenses · last filed 2026-08-06
- XERIS BIOPHARMA HOLDINGS, INC. operating costs and expenses for the quarter ending 2026-06-30 was $86.93M, a 29.63% increase year-over-year.
- XERIS BIOPHARMA HOLDINGS, INC. operating costs and expenses for the quarter ending 2026-03-31 was $75.21M, a 18.99% increase year-over-year.
- XERIS BIOPHARMA HOLDINGS, INC. operating costs and expenses for the quarter ending 2025-12-31 was $69.03M, a 18.17% increase year-over-year.
- XERIS BIOPHARMA HOLDINGS, INC. operating costs and expenses for the quarter ending 2025-09-30 was $67.65M, a 0.73% increase year-over-year.
- XERIS BIOPHARMA HOLDINGS, INC. operating costs and expenses for fiscal 2025 was $266.95M, a 12.77% increase from fiscal 2024.
- XERIS BIOPHARMA HOLDINGS, INC. operating costs and expenses for fiscal 2024 was $236.72M, a 13.85% increase from fiscal 2023.
- XERIS BIOPHARMA HOLDINGS, INC. operating costs and expenses for fiscal 2023 was $207.92M, a 8.19% increase from fiscal 2022.
- XERIS BIOPHARMA HOLDINGS, INC. operating costs and expenses for fiscal 2022 was $192.19M, a 16.66% increase from fiscal 2021.
| Period end | Operating Costs and Expenses 3 month | Operating Costs and Expenses 6 month | Operating Costs and Expenses 9 month | Operating Costs and Expenses 12 month |
|---|---|---|---|---|
| 2026-06-30 | $86.93M 10-Q · filed 2026-08-06 | $162.14M 10-Q · filed 2026-08-06 | $231.17M derived: sum of 3 quarters · filed 2026-08-06 | $298.82M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $75.21M 10-Q · filed 2026-05-07 | $144.25M derived: sum of 2 quarters · filed 2026-05-07 | $211.89M derived: sum of 3 quarters · filed 2026-05-07 | $278.95M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $69.03M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $136.68M derived: sum of 2 quarters · filed 2026-03-02 | $203.74M derived: sum of 3 quarters · filed 2026-08-06 | $266.95M 10-K · filed 2026-03-02 |
| 2025-09-30 | $67.65M 10-Q · filed 2025-11-06 | $134.71M derived: sum of 2 quarters · filed 2026-08-06 | $197.91M 10-Q · filed 2025-11-06 | $256.33M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $67.06M 10-Q · filed 2026-08-06 | $130.27M 10-Q · filed 2026-08-06 | $188.69M derived: sum of 3 quarters · filed 2026-08-06 | $255.85M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $63.21M 10-Q · filed 2026-05-07 | $121.63M derived: sum of 2 quarters · filed 2026-05-07 | $188.79M derived: sum of 3 quarters · filed 2026-05-07 | $245.04M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $58.42M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $125.58M derived: sum of 2 quarters · filed 2026-03-02 | $181.83M derived: sum of 3 quarters · filed 2026-03-02 | $236.72M 10-K · filed 2026-03-02 |
| 2024-09-30 | $67.16M 10-Q · filed 2025-11-06 | $123.41M derived: sum of 2 quarters · filed 2025-11-06 | $178.30M 10-Q · filed 2025-11-06 | $232.53M derived: sum of 4 quarters · filed 2026-03-02 |
| 2024-06-30 | $56.25M 10-Q · filed 2025-08-07 | $111.14M 10-Q · filed 2025-08-07 | $165.37M derived: sum of 3 quarters · filed 2026-03-02 | $218.60M derived: sum of 4 quarters · filed 2026-03-02 |
| 2024-03-31 | $54.88M 10-Q · filed 2025-05-08 | $109.11M derived: sum of 2 quarters · filed 2026-03-02 | $162.35M derived: sum of 3 quarters · filed 2026-03-02 | $216.33M derived: sum of 4 quarters · filed 2026-03-02 |
| 2023-12-31 | $54.23M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $107.46M derived: sum of 2 quarters · filed 2026-03-02 | $161.45M derived: sum of 3 quarters · filed 2026-03-02 | $207.92M 10-K · filed 2026-03-02 |
| 2023-09-30 | $53.23M 10-Q · filed 2024-11-08 | $107.22M derived: sum of 2 quarters · filed 2024-11-08 | $153.69M 10-Q · filed 2024-11-08 | $202.01M derived: sum of 4 quarters · filed 2025-03-06 |
| 2023-06-30 | $53.99M 10-Q · filed 2024-08-08 | $100.46M 10-Q · filed 2024-08-08 | $148.77M derived: sum of 3 quarters · filed 2025-03-06 | $197.28M derived: sum of 4 quarters · filed 2025-03-06 |
| 2023-03-31 | $46.47M 10-Q · filed 2024-05-09 | $94.79M derived: sum of 2 quarters · filed 2025-03-06 | $143.29M derived: sum of 3 quarters · filed 2025-03-06 | $187.51M derived: sum of 4 quarters · filed 2025-03-06 |
| 2022-12-31 | $48.31M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-06 | $96.82M derived: sum of 2 quarters · filed 2025-03-06 | $141.04M derived: sum of 3 quarters · filed 2025-03-06 | $192.19M 10-K · filed 2025-03-06 |
| 2022-09-30 | $48.51M 10-Q · filed 2023-11-09 | $92.73M derived: sum of 2 quarters · filed 2023-11-09 | $143.87M 10-Q · filed 2023-11-09 | $213.57M derived: sum of 4 quarters · filed 2024-03-06 |
| 2022-06-30 | $44.22M 10-Q · filed 2023-08-08 | $95.37M 10-Q · filed 2023-08-08 | $165.07M derived: sum of 3 quarters · filed 2024-03-06 | $200.49M derived: sum of 4 quarters · filed 2024-03-06 |
| 2022-03-31 | $51.15M 10-Q · filed 2023-05-09 | $120.85M derived: sum of 2 quarters · filed 2024-03-06 | $156.26M derived: sum of 3 quarters · filed 2024-03-06 | $190.96M derived: sum of 4 quarters · filed 2024-03-06 |
| 2021-12-31 | $69.70M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-06 | $105.12M derived: sum of 2 quarters · filed 2024-03-06 | $139.81M derived: sum of 3 quarters · filed 2024-03-06 | $164.75M 10-K · filed 2024-03-06 |
| 2021-09-30 | $35.42M 10-Q · filed 2022-11-09 | $70.11M derived: sum of 2 quarters · filed 2022-11-09 | $95.05M 10-Q · filed 2022-11-09 | |
| 2021-06-30 | $34.69M 10-Q · filed 2022-08-10 | $59.63M 10-Q · filed 2022-08-10 | ||
| 2021-03-31 | $24.93M 10-Q · filed 2022-05-11 | |||
| 2020-12-31 | $103.98M 10-K · filed 2022-03-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| Xencor Inc (XNCR) | United States | $1.776B | -7.33 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Septerna, Inc. (SEPN) | United States | $1.783B | -63.01 |